Retracted Article

Neurocognitive impairment and patient–proxy agreement on health-related quality of life evaluations in recurrent high-grade glioma patients

Datos Bibliográficos

ID15301360
AutoresIvan Caramanna (0000-0003-1520-499X, Amsterdam University Medical Centers, autor de correspondencia), Martin Klein (0009-0009-1265-649X, Amsterdam Neuroscience), Martin J van den Bent (0000-0001-5710-5127, Erasmus MC Cancer Institute), Martin van den Bent, Ahmed Idbaïh (0000-0001-5290-1204, Centre National de la Recherche Scientifique), Wolfgang Wick (0000-0002-6171-634X, German Cancer Research Center), Martin Taphoorn (0000-0001-9949-4722, Leiden University Medical Center), Martin J B Taphoorn, Linda Dirven (0000-0001-9157-9895, Leiden University Medical Center), Andrew Bottomley (0000-0002-9057-4600, European Organisation for Research and Treatment of Cancer), Jaap C Reijneveld (0000-0002-2257-3147, Amsterdam University Medical Centers)
Año2022
Volumen31
Número11
Páginas3253-3266
Fecha de publicación2022-08-18
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaQuality of Life Research (JOURNAL)
Identificadores de la revistaISSN: 0962-9343 • E-ISSN: 1573-2649
EditorialSpringer Science+Business Media (PUBLISHER • DE)
DOI10.1007/s11136-022-03197-w
PMID35982202
OpenAlexW4293067669
IdiomaEN
Referencias citadas23

While patient-proxy agreement on health-related quality of life outcomes is somewhat higher in cognitively intact patients, agreement in high-grade glioma patients is low in general. In light of these findings, we suggest to cautiously consider the use of proxy's evaluation in lieu of patient-reported outcomes, regardless of patient's neurocognitive status

Cognition · Concordance · Concordance correlation coefficient · Glioma · Mann–Whitney U test · Neurocognitive · Proxy (statistics · Psychiatry · Quality of life (healthcare · Wilcoxon signed-rank test · Cancer survivorship and care · Cancer-related cognitive impairment studies · Glioma Diagnosis and Treatment · Medicine · Internal Medicine